Home > News > Biotech Corp acquires exclusive worldwide license to nanotechnology platform
November 30th, 2007
Biotech Corp acquires exclusive worldwide license to nanotechnology platform
Abstract:
Malaysian Biotechnology Corporation (Biotech Corp) has acquired its first technology acquisition from Nanobiotix, a French start-up company, for an undisclosed amount.
Nanobiotix develops nanotechnology applications for cancer therapy. However, Biotech Corp is licensing the nanotechnology platform for non-cancer purposes.
Nanobiotix founder and chief executive officer Dr Laurent Levy said this would allow it to concentrate its resources on oncology applications while expanding its potential pipeline into non-cancer areas via Biotech Corp.
The license will provide access to the application of high-level nanotechnology in the country, said BioTech Corp chief executive officer Datuk Iskandar Mizal Mahmood at the launch on Nov 30.
Source:
theedgedaily.com
Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||